Strengthening the Screening of Lung Cancer in Europe (SOLACE) is a pioneering new EU4Health project under the Europe’s Beating Cancer Plan, which will facilitate implementation of lung cancer screening programmes across Europe, breaking down the barriers to screening to ensure people across all social and economic groups can access it.
Lung cancer is the leading cause of death from cancer. As with all cancers, survival rates are much higher when it is caught early.
Low-dose computed tomography scans (LDCT) are a safe, simple, and effective way of screening for lung cancer. Multiple trials in the USA and Europe have shown that LDCT, when effectively implemented, can reduce deaths from lung cancer by 20%. The new EU Cancer Screening Recommendation invites Member States to explore the feasibility and effectiveness of LDCT to screen individuals at high risk for lung cancer. The EU-funded SOLACE project supports Member States with implementation and will provide a personalised toolbox to national and regional centres to facilitate the implementation of lung-cancer screening programmes across the EU, with a particular focus on groups that are at higher risk due to health inequalities.
The project brings together 33 partners from all over Europe, and the SOLACE consortium will be implemented under the scientific leadership of experts appointed by the European Society of Radiology and the European Respiratory Society.
In the long term the project will provide valuable learning on how best to implement a cost-effective screening programme for lung cancer and the best techniques for reaching out to those groups that are at particularly high risk. This will ensure that those as most risk of lung cancer have access to high quality screening in a way that fits their needs.
Visit the website, Facebook, Instagram or LinkedIn page and look for the #SOLACELUNG on Twitter for the latest updates on the SOLACE project.
Facts and figures
Coordinator: European Institute for Biomedical Imaging Research (EIBIR)
Number of Partners: 33
Start Date: April 1, 2023
End Date: March 31, 2026
Total EC Funding: € 9,707,367.11
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101101187.
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.